Summary
Sodium 8-(2-hydroxybenzamido)octanoate (SNAC) is utilized as an oral absorption enhancer, gaining attention for its potential in delivering oral forms of heparin and insulin. Salcaprozate sodium enhances passive transcellular penetration of small intestinal epithelial cells by augmenting lipophilicity through non-covalent macromolecular complexation.
Key Information
Molecular Weight: 301.32
Molecular Formula: C15H20NNaO4
Purity: 98.0%~102.0% on an anhydrous basis
Chiasma, an Israeli company, established a TPE technology absorption promotion platform based on sodium octanoate's characteristics. This technology was successfully employed in preparing oral octreotide. The formulation comprises medium-chain fatty acids, sodium octanoate, and other excipients, combined with octreotide in an oily suspension. It is then encapsulated in a pH-dependent polymer enteric coating. In June 2020, the U.S. FDA approved the somatostatin analog octreotide enteric-coated capsules (Mycapssa) for the long-term maintenance treatment of acromegaly patients. Sodium octanoate influences the fluidity of the gastrointestinal tract membrane, enhancing cell permeability and increasing protein release within cells.
Preparation of Stock Solution
Solvent: DMSO
Concentration: 50 mg/ml (165.94 mM; Requires ultrasonication)
Note: Solubility may vary in different solvents; choose an appropriate solvent to avoid compromising product effectiveness. Refrain from repeated freezing and thawing, as it can impact the product's efficacy.